LATEST INSIGHTS
Can biotech bounce back?
Biotechnology stocks have been suffering a decline for some months. But while the sector faces some challenges, attractive valuations and a rapid pace of medical innovation could become difficult for investors to ignore, says Portfolio Manager Andy Acker.
The haves and have-nots of US high yield
In this video, Rebecca Young, Portfolio Manager within the Strategic Fixed Income team, explains why there is more than meets the eye in the US high yield market and discusses the teams approach to achieving ‘sensible income’.
Growth slowing but precipitous drop unlikely
A new video, ‘Growth slowing but precipitous drop unlikely’, is now available on the blog.
Although the current economic expansion is ageing (bringing us nearer to a recession) leading indicators do not indicate a sharp contraction. What does that mean for equity investors? Director of Research Carmel Wellso explains.
FEATURED FUNDS
JBALX
Balanced Fund
For 25 years, this dynamic allocation strategy has delivered our equity and fixed income expertise in a one-stop core solution.
JFNIX
Global Life Sciences Fund
By understanding the science and business of health care, our experienced team invests in companies addressing unmet medical needs or improving efficiencies.
JATIX
Global Technology Fund
Our deep and experienced tech team seeks growth through innovation in this complex and dynamic sector.